Stanley Laman Group Ltd. Invests $3.50 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Stanley Laman Group Ltd. bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 144,428 shares of the biopharmaceutical company's stock, valued at approximately $3,502,000. Stanley Laman Group Ltd. owned 0.12% of Catalyst Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Castlekeep Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $37,494,000. Bank of America Corp DE boosted its stake in Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock worth $32,741,000 after purchasing an additional 913,843 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock worth $14,570,000 after purchasing an additional 396,506 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after purchasing an additional 390,116 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $6,887,000. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

CPRX traded down $0.76 during trading on Friday, reaching $23.53. 1,112,686 shares of the stock were exchanged, compared to its average volume of 1,129,972. The stock's 50 day moving average price is $23.85 and its two-hundred day moving average price is $22.87. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.75 and a twelve month high of $26.58. The stock has a market cap of $2.87 billion, a P/E ratio of 19.94, a price-to-earnings-growth ratio of 3.31 and a beta of 0.72.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider now owns 41,081 shares in the company, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 247,924 shares of company stock worth $5,879,369 in the last ninety days. Insiders own 10.40% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on CPRX. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird raised their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Finally, Stephens reissued an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.